CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

AspirinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (10)

Name (Synonyms) Correlation
drug3137 XCEL-UMC-BETA Wiki 0.58
drug1439 Interferon-Beta Wiki 0.58
drug240 Apixaban 2.5 MG Wiki 0.58
drug1840 Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR Wiki 0.58
drug241 Apixaban 5MG Wiki 0.58
drug2633 Simvastatin Wiki 0.41
drug2458 Rivaroxaban Wiki 0.26
drug1607 Losartan Wiki 0.20
drug703 Colchicine Wiki 0.18
drug2122 Placebo Wiki 0.06

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D013927 Thrombosis NIH 0.13
D013577 Syndrome NIH 0.06
D055371 Acute Lung Injury NIH 0.06
D012127 Respiratory Distress Syndrome, Newborn NIH 0.05
D012128 Respiratory Distress Syndrome, Adult NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 3 clinical trials

Clinical Trials

1 Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial

ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19.

NCT04324463 Coronavirus Severe Acute Respiratory Syndrome Drug: Colchicine Drug: Interferon-Beta Drug: Aspirin Drug: Rivaroxaban
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: composite of hospitalization or death

Measure: Outpatient trial - Colchicine vs. control and Aspirin vs. control

Time: 45 days post randomization

Description: invasive mechanical ventilation or death

Measure: Inpatient trial - Interferon-β vs. control and Colchicine vs. control

Time: 45 days post randomization

Description: invasive mechanical ventilation or death

Measure: Inpatient trial - Aspirin and rivaroxaban vs. control

Time: 45 days post randomization

Secondary Outcomes

Description: disease progression by 2 points on a 7-point scale

Measure: Outpatient and Inpatient trials - Colchicine vs. control, Interferon-β vs. control

Time: 45 days post randomization

Description: composite of major adverse cardiovascular events (MI, stroke, ALI, VTE, death), and disease progression by 2 points on a 7-point scale

Measure: Outpatient and Inpatient trials - Aspirin vs. control, Aspirin and rivaroxaban vs. control

Time: 45 days post randomization

2 Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

NCT04343001 Covid-19 Drug: Aspirin Drug: Losartan Drug: Simvastatin

Primary Outcomes

Description: Cause of death will be described

Measure: Death

Time: up to 28 days of randomisation

Secondary Outcomes

Measure: Myocardial infarction

Time: up to 28 days of randomisation

Measure: Congestive cardiac failure

Time: up to 28 days of randomisation

Measure: Severe cardiac arrythmia

Time: up to 28 days of randomisation

Measure: Myocarditis

Time: up to 28 days of randomisation

Measure: Respiratory failure including ARDS

Time: up to 28 days of randomisation

Measure: Viral pneumonitis

Time: up to 28 days of randomisation

Measure: Acute renal failure

Time: up to 28 days of randomisation

Measure: Sepsis

Time: up to 28 days of randomisation

Measure: Stroke

Time: up to 28 days of randomisation

Measure: Gastrointestinal bleeding

Time: up to 28 days of randomisation

Measure: Receipt of non invasive or mechanical ventilation

Time: up to 28 days of randomisation

Measure: Ability to self care at hospital discharge

Time: up to 28 days of randomisation

3 COVID-19 Outpatient Thrombosis Prevention Trial: A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis

A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis

NCT04498273 COVID-19 Drug: Apixaban 2.5 MG Drug: Apixaban 5MG Drug: Aspirin Drug: Placebo
MeSH:Thrombosis

Primary Outcomes

Description: The primary outcome will be a composite endpoint of need for hospitalization for cardiovascular/pulmonary events, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, ischemic stroke, and all-cause mortality for up to 45 days after initiation of assigned treatment.

Measure: Primary

Time: 45 days

No related HPO nodes (Using clinical trials)